Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

doi:10.1016/j.lanepe.2021.100171

. 2021 Sep:8:100171.

doi: 10.1016/j.lanepe.2021.100171. Epub 2021 Jul 13.

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Tiffany Charmet¹, Laura Schaeffer¹, Rebecca Grant^{1

2}, Simon Galmiche¹, Olivia Chény³, Cassandre Von Platen³, Alexandra Maurizot⁴, Alexandra Rogoff⁴, Faïza Omar⁵, Christophe David⁵, Alexandra Septfons⁶, Simon Cauchemez⁷, Alexandre Gaymard^{8

9}, Bruno Lina^{8

9}, Louise H Lefrancois^{10

11}, Vincent Enouf^{10

11

12}, Sylvie van der Werf^{10

11}, Alexandra Mailles⁶, Daniel Levy-Bruhl⁶, Fabrice Carrat¹³, Arnaud Fontanet^{1

14}

Affiliations

¹ Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
² Sorbonne University, Paris, France.
³ Institut Pasteur, Centre for Translational Research, Paris, France.
⁴ Caisse Nationale d'Assurance Maladie, Paris, France.
⁵ Institut IPSOS, Paris, France.
⁶ Santé Publique France, Saint-Maurice, France.
⁷ Institut Pasteur, Mathematical Modelling of Infectious Diseases Unit; UMR2000; CNRS, Paris, France.
⁸ CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon.
⁹ Virpath, Centre International de Recherche En Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
¹⁰ Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569; Université de Paris, Paris, France.
¹¹ National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
¹² Mutualized Platform of Microbiology, Pasteur International Bioresources Network, Institut Pasteur, Paris, France.
¹³ Sorbonne Université, Inserm, IPLESP, hôpital Saint-Antoine, APHP, 27 rue Chaligny, Paris F75571, France.
¹⁴ Conservatoire national des arts et métiers, Unité PACRI, Paris, France.

PMID: 34278372
PMCID: PMC8277121
DOI: 10.1016/j.lanepe.2021.100171

Free PMC article

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Tiffany Charmet et al. Lancet Reg Health Eur. 2021 Sep.

Free PMC article

. 2021 Sep:8:100171.

doi: 10.1016/j.lanepe.2021.100171. Epub 2021 Jul 13.

Authors

Affiliations

¹ Institut Pasteur, Emerging Diseases Epidemiology Unit, Paris, France.
² Sorbonne University, Paris, France.
³ Institut Pasteur, Centre for Translational Research, Paris, France.
⁴ Caisse Nationale d'Assurance Maladie, Paris, France.
⁵ Institut IPSOS, Paris, France.
⁶ Santé Publique France, Saint-Maurice, France.
⁷ Institut Pasteur, Mathematical Modelling of Infectious Diseases Unit; UMR2000; CNRS, Paris, France.
⁸ CNR des Virus des Infections Respiratoires, Institut des Agents Infectieux, Hospices Civils de Lyon.
⁹ Virpath, Centre International de Recherche En Infectiologie, Université de Lyon, Inserm U1111, CNRS UMR5308, École Normale Supérieure de Lyon, UCBL, Lyon, France.
¹⁰ Molecular Genetics of RNA Viruses, Department of Virology, Institut Pasteur CNRS UMR 3569; Université de Paris, Paris, France.
¹¹ National Reference Center for Respiratory Viruses, Institut Pasteur, Paris, France.
¹² Mutualized Platform of Microbiology, Pasteur International Bioresources Network, Institut Pasteur, Paris, France.
¹³ Sorbonne Université, Inserm, IPLESP, hôpital Saint-Antoine, APHP, 27 rue Chaligny, Paris F75571, France.
¹⁴ Conservatoire national des arts et métiers, Unité PACRI, Paris, France.

PMID: 34278372
PMCID: PMC8277121
DOI: 10.1016/j.lanepe.2021.100171

Abstract

Background: We aimed to assess the effectiveness of two doses of mRNA COVID-19 vaccines against COVID-19 with the original virus and other lineages circulating in France.

Methods: In this nationwide case-control study, cases were SARS-CoV-2 infected adults with onset of symptoms between 14 February and 3 May 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire on recent activity-related exposures and vaccination history. Information about the infecting virus was based on a screening RT-PCR for either B.1.1.7 or B.1.351/P.1 variants.

Findings: Included in our analysis were 7 288 adults infected with the original SARS-CoV-2 virus, 31 313 with the B.1.1.7 lineage, 2 550 with B.1.351/P1 lineages, and 3 644 controls. In multivariable analysis, the vaccine effectiveness (95% confidence interval) seven days after the second dose of mRNA vaccine was estimated at 88% (81-92), 86% (81-90) and 77% (63-86) against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively. Recent (2 to 6 months) history of virologically confirmed SARS-CoV-2 infection was found to be 83% (76-88), 88% (85-91) and 83% (71-90) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively; and more distant (> 6 months) infections were 76% (54-87), 84% (75-90), and 74% (41-89) protective against COVID-19 with the original virus, the B.1.1.7 lineage, and the B.1.351/P.1 lineages, respectively.

Interpretation: In real-life settings, two doses of mRNA vaccines proved to be effective against COVID-19 with the original virus, B.1.1.7 lineage and B.1.351/P.1 lineages.

Funding: Institut Pasteur, Research & Action Emerging Infectious Diseases (REACTing), Fondation de France (Alliance "Tous unis contre le virus").

Keywords: COVID-19; SARS-CoV-2 variants; Vaccine effectiveness; case-control study; epidemiology.

PubMed Disclaimer

Conflict of interest statement

All authors have nothing to declare.

Cited by

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.
Saha T, Sinha S, Harfoot R, Quiñones-Mateu ME, Das SC. Saha T, et al. Pharmaceutics. 2022 Jul 8;14(7):1432. doi: 10.3390/pharmaceutics14071432. Pharmaceutics. 2022. PMID: 35890327 Free PMC article.
A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant.
To A, Wong TAS, Lieberman MM, Thompson K, Ball AH, Pessaint L, Greenhouse J, Daham N, Cook A, Narvaez B, Flinchbaugh Z, Van Ry A, Yalley-Ogunro J, Andersen Elyard H, Lai CY, Donini O, Lehrer AT. To A, et al. ACS Infect Dis. 2022 Apr 8;8(4):825-840. doi: 10.1021/acsinfecdis.1c00600. Epub 2022 Mar 9. ACS Infect Dis. 2022. PMID: 35263081 Free PMC article.
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.
Alexandre M, Marlin R, Prague M, Coleon S, Kahlaoui N, Cardinaud S, Naninck T, Delache B, Surenaud M, Galhaut M, Dereuddre-Bosquet N, Cavarelli M, Maisonnasse P, Centlivre M, Lacabaratz C, Wiedemann A, Zurawski S, Zurawski G, Schwartz O, Sanders RW, Le Grand R, Levy Y, Thiébaut R. Alexandre M, et al. Elife. 2022 Jul 8;11:e75427. doi: 10.7554/eLife.75427. Elife. 2022. PMID: 35801637 Free PMC article.
SARS-CoV-2: phenotype, genotype, and characterization of different variants.
Saberiyan M, Karimi E, Khademi Z, Movahhed P, Safi A, Mehri-Ghahfarrokhi A. Saberiyan M, et al. Cell Mol Biol Lett. 2022 Jun 17;27(1):50. doi: 10.1186/s11658-022-00352-6. Cell Mol Biol Lett. 2022. PMID: 35715738 Free PMC article.
Vaccine effectiveness against COVID-19 hospitalization in adults in France: A test negative case control study.
Luong Ngyen LB, Bauer R, Lesieur Z, Galtier F, Duval X, Vanhems P, Lainé F, Tattevin P, Durier C, Launay O; FLUVAC Study group. Luong Ngyen LB, et al. Infect Dis Now. 2022 Feb;52(1):40-43. doi: 10.1016/j.idnow.2021.12.002. Epub 2021 Dec 15. Infect Dis Now. 2022. PMID: 34920180 Free PMC article.

See all "Cited by" articles

References

1. N Engl J Med. 2021 Jun 24;384(25):2453-2454 - PubMed
1. Euro Surveill. 2021 Mar;26(9): - PubMed
1. N Engl J Med. 2021 Apr 15;384(15):1412-1423 - PubMed
1. Nat Commun. 2021 Feb 10;12(1):905 - PubMed
1. Vaccine. 2015 Mar 24;33(13):1541-8 - PubMed

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

[1] N Engl J Med. 2021 Jun 24;384(25):2453-2454 - PubMed

[2] N Engl J Med. 2021 Jun 24;384(25):2453-2454 - PubMed

[3] Euro Surveill. 2021 Mar;26(9): - PubMed

[4] Euro Surveill. 2021 Mar;26(9): - PubMed

[5] N Engl J Med. 2021 Apr 15;384(15):1412-1423 - PubMed

[6] N Engl J Med. 2021 Apr 15;384(15):1412-1423 - PubMed

[7] Nat Commun. 2021 Feb 10;12(1):905 - PubMed

[8] Nat Commun. 2021 Feb 10;12(1):905 - PubMed

[9] Vaccine. 2015 Mar 24;33(13):1541-8 - PubMed

[10] Vaccine. 2015 Mar 24;33(13):1541-8 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Affiliations

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Miscellaneous